INTERRELATIONSHIPS AMONG MEASURES OF AUTONOMIC ACTIVITY AND CARDIOVASCULAR RISK-FACTORS DURING ORTHOSTASIS AND THE ORAL GLUCOSE-TOLERANCE TEST

被引:17
作者
PELES, E
GOLDSTEIN, DS
AKSELROD, S
NITZAN, H
AZARIA, M
ALMOG, S
DOLPHIN, D
HALKIN, H
MODAN, M
机构
[1] CHAIM SHEBA MED CTR, DEPT CLIN EPIDEMIOL, IL-52621 TEL HASHOMER, ISRAEL
[2] CHAIM SHEBA MED CTR, DEPT ORTHOPAED REHABIL, IL-52621 TEL HASHOMER, ISRAEL
[3] CHAIM SHEBA MED CTR, DIV CLIN PHARMACOL & TOXICOL, IL-52621 TEL HASHOMER, ISRAEL
[4] TEL AVIV UNIV, SCH PHYS & ASTRON, RAMAT AVIV, ISRAEL
[5] NINCDS, CLIN NEUROSCI BRANCH, BETHESDA, MD 20892 USA
关键词
STRESS; SYMPATHETIC NERVOUS SYSTEM; CATECHOLAMINES; PARASYMPATHETIC NERVOUS SYSTEM; HEART RATE; SPECTRAL ANALYSIS;
D O I
10.1007/BF01818892
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Overstimulation of sympathetic nervous system activity is related to atherosclerotic cardiovascular disease risk, but the role of parasympathetic activity in this association is not clear. This study evaluated sympathetic and parasympathetic function by spectral analysis of heart rate variability and plasma levels of norepinephrine (NE) epinephrine (EPI), dihydroxyphenylglycol (DHPG), dihydroxyphenylalanine (DOPA) and dihydroxyphenylacetic acid (DOPAC). It also examined the interrelationships among these parameters and established atherosclerotic cardiovascular disease risk factors in 53 men (mean age 59.5 years). During supine rest, low-frequency power correlated positively with high-frequency power (r = 0.58, p < 0.001), plasma NE correlated with plasma DHPG (r = 0.41, p < 0.001) and plasma DOPA with DOPAC (r = 0.47, p < 0.001) but neither low- nor high-frequency power was correlated with plasma levels of any catechol. Among risk factors, plasma NE correlated with fasting insulin and mean arterial blood pressure, and urine NE correlated with body mass index. Both low- and high-frequency power correlated positively with insulin levels. Orthostasis decreased high-frequency power and increased low-frequency power and plasma NE levels. During the oral glucose tolerance test, both high- and low-frequency power increased, plasma NE levels were unchanged, and plasma EPI levels decreased [88.5 +/- 18 (SEM) versus 52.5 +/- 12 pM, p = 0.001]. The results suggest that orthostasis decreases and the oral glucose tolerance test increases parasympathetic outflows, whereas both stimuli increase sympathetic outflows. Among all atherosclerotic cardiovascular disease risk factors, hyperinsulinaemia showed the strongest association with autonomic nervous system activity, especially parasympathetic activity. Estimates of sympathetic responses obtained from power spectral analysis of heart rate variability agree poorly with those from plasma levels of catechols, possibly because of a parasympathetic contribution to low-frequency power and independence of sympathoneural outflows to the arm and heart.
引用
收藏
页码:271 / 278
页数:8
相关论文
共 50 条
[1]   HEMODYNAMIC REGULATION - INVESTIGATION BY SPECTRAL-ANALYSIS [J].
AKSELROD, S ;
GORDON, D ;
MADWED, JB ;
SNIDMAN, NC ;
SHANNON, DC ;
COHEN, RJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 249 (04) :H867-H875
[2]   DISSOCIATION OF SYMPATHETIC-NERVE ACTIVITY IN ARM AND LEG MUSCLE DURING MENTAL STRESS [J].
ANDERSON, EA ;
WALLIN, BG ;
MARK, AL .
HYPERTENSION, 1987, 9 (06) :114-119
[3]   HYPERINSULINEMIA PRODUCES BOTH SYMPATHETIC NEURAL ACTIVATION AND VASODILATION IN NORMAL HUMANS [J].
ANDERSON, EA ;
HOFFMAN, RP ;
BALON, TW ;
SINKEY, CA ;
MARK, AL .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :2246-2252
[4]   THE SYMPATHETIC RESPONSE TO EUGLYCEMIC HYPERINSULINEMIA - EVIDENCE FROM MICROELECTRODE NERVE RECORDINGS IN HEALTHY-SUBJECTS [J].
BERNE, C ;
FAGIUS, J ;
POLLARE, T ;
HJEMDAHL, P .
DIABETOLOGIA, 1992, 35 (09) :873-879
[5]   DIRECT MUSCARINIC CHOLINERGIC INHIBITION OF HEPATIC GLUCOSE-PRODUCTION IN HUMANS [J].
BOYLE, PJ ;
LIGGETT, SB ;
SHAH, SD ;
CRYER, PE .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (02) :445-449
[6]  
BREUER HWM, 1993, BRIT HEART J, V70, P144
[7]   SYMPATHETIC NERVOUS ACTIVITY DURING EXERCISE [J].
CHRISTENSEN, NJ ;
GALBO, H .
ANNUAL REVIEW OF PHYSIOLOGY, 1983, 45 :139-153
[8]  
DZAU VJ, 1987, J CARDIOVASC PHARM, V10, pS2
[9]  
EFENDIC S, 1991, J INTERN MED, V229, P9
[10]  
EISENHOFER G, 1986, CLIN CHEM, V32, P2030